A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

December 4, 2029

Study Completion Date

December 4, 2031

Conditions
Propionic Acidemia
Interventions
BIOLOGICAL

mRNA-3927

mRNA-3927 dispersion for IV infusion

Trial Locations (12)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

19104

RECRUITING

The Children's Hospital of Philadelphia (CHOP), Philadelphia

27710

RECRUITING

Duke University Medical System (Duke Health), Durham

48109

RECRUITING

University of Michigan Hospitals, Ann Arbor

77030

RECRUITING

Texas Children's Hospital, Houston

90095

RECRUITING

Ronald Reagan UCLA Medical Center, Los Angeles

M5G 1X8

RECRUITING

Hospital For Sick Children, Toronto

470-1192

NOT_YET_RECRUITING

Fujita Health University Hospital, Toyoake-shi

M13 9WL

RECRUITING

Willink Biochemical Genetics Unit - Manchester, Manchester

B15 2TH

RECRUITING

University Hospital Birmingham NHS Foundation Trust, Birmingham

B4 6NH

COMPLETED

Birmingham Women's and Children's NHS Foundation Trust, Birmingham

WC1N 3JH

RECRUITING

Great Ormond Street Hospital for Children NHS Foundation Trust, London

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY